Next Generation Microbial Therapeutics: Transforming the Therapeutic Landscape for Atopy & Asthma

May 12, 2017

Lunch Seminar, Amgen Innovator Series

[clear]

Nikole E. Kimes, PhD
Co-Founder & VP, Siolta Therapeutics

Siolta Therapeutics is designing microbial therapeutics aimed at the prevention and treatment of inflammatory diseases. They are currently focused on the rational design of a mixed-species therapeutic microbial consortium to treat airway inflammation. Ultimately working towards a future in which the microbiome can help drive patient stratification and tailored microbial therapeutics.

About Nikole Kimes

Nikole Kimes, PhD, is Co-Founder and Vice President of Siolta Therapeutics. Nikole’s was trained as an environmental and human microbial ecologist – most recently as a postdoctoral scholar in the laboratory of Dr. Susan Lynch at UCSF, which provided the foundation for Siolta Therapeutics. Her efforts at Siolta leverage microbiota data to improve patient stratification and develop microbial therapeutics to re-engineer microbiome composition and metabolic function in the gastrointestinal tract.